Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M31,451Revenue $M1,551Net Margin (%)16.3Z-Score30.3
Enterprise Value $M30,022EPS $1.3Operating Margin %34.0F-Score6
P/E(ttm))96.8Cash Flow Per Share $0.8Pre-tax Margin (%)33.9Higher ROA y-yN
Price/Book11.410-y EBITDA Growth Rate %0Quick Ratio5.3Cash flow > EarningsY
Price/Sales16.75-y EBITDA Growth Rate %52.4Current Ratio5.7Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %37.4ROA % (ttm)7.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)10.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M198ROI % (ttm)16.0Gross Margin Increase y-yN

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 163.683%New holding, 50371 sh.50,371
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 163.683%New holding, 1318 sh.1,318
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 163.683%New holding, 5026 sh.5,026
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 163.683%New holding, 10218 sh.10,218
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 163.683%Reduce -28.52%5,268,418
ALXNFrank Sands 2013-09-30 Reduce-0.27%$94.34 - $117.28
($109.83)
$ 163.6849%Reduce -10.5%7,540,405
ALXNFrank Sands 2013-03-31 Add0.11%$83.39 - $102.57
($93.13)
$ 163.6876%Add 4.23%8,420,336
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 163.6876%Sold Out0
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 163.6867%New holding, 12977 sh.12,977
ALXNFrank Sands 2012-06-30 Add0.27%$83.74 - $98.82
($91.04)
$ 163.6880%Add 6.43%9,739,804
ALXNGeorge Soros 2012-06-30 Sold Out -0.07%$83.74 - $98.82
($91.04)
$ 163.6880%Sold Out0
ALXNGeorge Soros 2012-03-31 Buy 0.07%$70.29 - $94.31
($75.85)
$ 163.68116%New holding, 50000 sh.50,000
ALXNJoel Greenblatt 2011-09-30 Sold Out -0.0882%$47.81 - $66.99
($56.19)
$ 163.68191%Sold Out0
ALXNJoel Greenblatt 2011-06-30 Buy 0.09%$44.61 - $52.195
($47.91)
$ 163.68242%New holding, 13417 sh.13,417
ALXNGeorge Soros 2011-06-30 Sold Out $44.61 - $52.195
($47.91)
$ 163.68242%Sold Out0
ALXNGeorge Soros 2011-03-31 Add$20.14 - $24.93
($22.51)
$ 163.68627%Add 90.48%4,000
ALXNGeorge Soros 2010-12-31 Reduce$31.78 - $41.17
($36.65)
$ 163.68347%Reduce -87.61%4,200
ALXNGeorge Soros 2010-09-30 Buy 0.03%$24.99 - $32.49
($28.22)
$ 163.68480%New holding, 33900 sh.33,900
ALXNGeorge Soros 2010-06-30 Sold Out -0.17%$24.31 - $28.34
($26.54)
$ 163.68517%Sold Out0
ALXNGeorge Soros 2010-03-31 Add0.06%$22.75 - $27.7
($24.88)
$ 163.68558%Add 51.77%214,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALXN John Burbank 2014-03-311,31800.01New Buy
ALXN Joel Greenblatt 2014-03-315,02600.01New Buy
ALXN Ron Baron 2014-03-3110,2180.010.01New Buy
ALXN Ray Dalio 2014-03-3150,3710.030.06New Buy
ALXN Frank Sands 2014-03-315,268,4182.662.1-28.52%
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELL LEONARDCEO 2014-07-30Sell127,289$162.930.46view
BELL LEONARDCEO 2014-06-20Sell90,280$163.60.05view
MACKAY MARTINEVP & Global Head of R&D 2014-06-12Sell25,000$166.42-1.65view
KELLER WILLIAM RDirector 2014-06-05Sell3,425$170-3.72view
Veneman Ann MDirector 2014-06-04Sell1,236$170.01-3.72view
BELL LEONARDCEO 2014-05-27Sell70,000$166.16-1.49view
BELL LEONARDCEO 2014-05-20Sell70,000$155.964.95view
MACKAY MARTINEVP & Global Head of R&D 2014-05-14Sell3,574$160.851.76view
PARVEN ALVIN SDirector 2014-05-13Sell12,276$160.781.8view
BELL LEONARDCEO 2014-04-29Sell70,000$156.24.79view

Press Releases about ALXN :

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
fv 107 Apr 01 2013 
Weekly Top Insider Sells: GOOG, KSS, ALXN, and QCOM Sep 03 2012 
Weekly Top Insider Sells: GOOG, YHOO, ALXN, and CTL Jun 04 2012 
Alexion is Betting on Soliris and a Little Charity Mar 06 2012 


More From Other Websites
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 30 2014
Biotech ETF Price Swings May Signal Need For Caution Jul 28 2014
Midday movers: Cummins, Dollar Tree, Zillow & More Jul 28 2014
ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 25 2014
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 24 2014
Celgene, Alexion Beat Estimates, But Biotechs Fall Jul 24 2014
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View Jul 24 2014
Biotechs beat estimates, but the Street wants more Jul 24 2014
Video: Celgene, Alexion Earnings Top, But Stocks Fall Jul 24 2014
Q2 2014 Alexion Pharmaceuticals, Inc. Earnings Release - Before Market Open Jul 24 2014
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a... Jul 24 2014
Alexion Reports Second Quarter 2014 Results Jul 24 2014
Alexion Reports Second Quarter 2014 Results Jul 24 2014
Alexion's hypophosphatasia candidate MAA accepted by European Medicines Agency Jul 24 2014
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a... Jul 24 2014
Will Alexion Pharmaceuticals (ALXN) Miss This Earnings Season? Jul 23 2014
S&P 500 Posts New High; Biotechs, Airlines, Builders Up Jul 23 2014
S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade Jul 23 2014
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 Jul 23 2014
Video: Biogen Trounces Q2 Estimates On Tecfidera Jul 23 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide